Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$3.19 USD
-0.02 (-0.62%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.18 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TARA 3.19 -0.02(-0.62%)
Will TARA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARA
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
TARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TARA
Is TARA ready to move higher? 20 Day Moving Average Support shows up after sliding 0.62%
Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks
Crossed Above 20 Day Moving Average appears for TARA after 5.94% move
Stochastic Reached Oversold appears for TARA after 1.3% move
Citizens JMP healthcare analysts hold an analyst/industry conference call